Impact of 12-Week Creatine HCl Supplementation on Body Composition, Functional Muscle and Brain Performance, Blood Biomarkers, and Tissue Creatine Levels in Older Adults With Sarcopenia

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The CONCRET-SARCOPA trial is a 12-week, double-blind, randomized controlled study designed to evaluate the efficacy of creatine HCl supplementation in older adults with sarcopenia. The trial investigates whether daily creatine HCl improves body composition, enhances functional muscle and cognitive performance, and favorably alters key blood biomarkers associated with muscle health and metabolic status. Additionally, the study assesses changes in tissue creatine levels using non-invasive and biochemical methods to clarify mechanistic responses to supplementation. Findings from this trial will provide critical evidence on the therapeutic potential of creatine HCl as a targeted nutritional strategy for managing sarcopenia in the geriatric population.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Healthy Volunteers: t
View:

• Age \> 60 years

• Low muscle strength by handgrip (SDOC criteria for sarcopenia): \< 35.5 kg in men and \< 20 kg in women

• Sign free and informed consent

• Demonstrate interest, conditions and availability to participate

Locations
Other Locations
Serbia
Center for Health Sciences
RECRUITING
Belgrade
Contact Information
Primary
Sergej Ostojic, MD, PhD
sergej.ostojic@chess.edu.rs
+381112643242
Backup
Nikola Todorovic
nikola.todorovic@appliedbioenergetics.org
+381112643242
Time Frame
Start Date: 2025-12-01
Estimated Completion Date: 2026-09-15
Participants
Target number of participants: 30
Treatments
Experimental: Experimental 1
2 capsules of creatine HCl per day
Placebo_comparator: Experimental 2
2 capsules of inulin HCl per day
Related Therapeutic Areas
Sponsors
Leads: Center for Health Sciences, Serbia

This content was sourced from clinicaltrials.gov